Pharmacoeconomics of lipid lowering therapy in Ireland

Irish Medical Journal

Volumn 92, Issue 7, 1999, Pages 430-432

  Barry, M ^a   Heerey, A ^a   Sheehan, O ^a   Ryan, M ^a   McCulloch, D ^a   Feely, J ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT;

CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; IRELAND; MALE; PHARMACOECONOMICS; REVIEW;

ANTILIPEMIC AGENTS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; IRELAND; MALE;

EID: 0033222324     PISSN: 03323102     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kanavos P. Single European currency and Monetary Union. Macroeconomic Implications for Pharmaceutical Spending. Pharmacoeconomics 1998; 13: 9-20.
2. Marchant N. Drivers of the growth in medicines expenditure. Office of Health Economics, London. 1997; 12-25.
3. General Medical Services Payments Board. Report for the year ending 31st December 1998.
4. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
5. Sacks FM, Pfeffer MA, Moye LA. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 1996; 335: 1001-1009.
6. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998; 339: 1349-1357.
7. Shepherd J. Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 1995; 333: 1301-1307.
8. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-1622.
9. Goa KL, Barradell LB and McTavish D. Simvastatin: A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease. Pharmacoeconomics 1997; 11: 89-110.
10. Johannesson M, Jonsson B, Kjekshus J et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N. Engl. J. Med. 1997; 336:332-336.
11. Goldman L, Garber AM, Grover SA et al. Task force 6. Cost effectiveness of assessment and management of risk factors. J. Am Coll Cardiol 1996: 1020-1030.
12. Jonsson B, Johannesson M, Kjekshus J et al. Cost effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur. Heart J. 1996; 17: 1001-1017.
13. Reckless JPD. The 4S study and its pharmacoeconomic implications. Pharmacoeconomics. 1996. 101-105.
14. Caro J, Klittich W, McGuire A et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577-1582.
15. Coukell AJ and Wilde MI. Pravastatin: A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease. Pharmacoeconomics 1998; 14 (2):217-236.
16. Martens LL, Guibert R. Cost effectiveness analysis of lipid modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther; 1994 16 (6): 1052-1062.
17. Huse DM, Russell MW, Kraemer DF et al. Cost effectiveness of HMG-CoA reductase inhibition in primary prevention of CHD: new evidence comparing all available agents [abstract no. LC-21]. Association for Pharmacoeconomics and Outcomes Research: The APOR Lipid Conference. 1997 Nov 5, 6, 7: Orlando, Florida.
18. Elliot WJ, Weir DR. Comparative cost effectiveness of HMG-CoA reductase inhibitors in secondary prevention of myocardial infarction [abstract no. LC-15]. Association for Pharmacoeconomics and Outcomes Research: The APOR Lipid Conference 1997. Nov 5, 6, 7: Orlando, Florida..
19. Smith DG, Leslie SJ, Szucs TD et al. Cost of treating to a modified European atherosclerosis society LDL - C target: Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin. Clin Drug Invest. 1999; 17 (8): 185-193.
20. Huse DM, Russell MW, Miller JD. Cost effectiveness of statins. Am J. Cardiol. 1998; 82:1357-1363.
21. Ramsey LE, Haq IU, Jackson PR et al. Targeting lipid lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996; 348: 387-388.
22. General Medical Services Payments Board. Financial and Statistical Analysis of claims and payments 1998.